AstraZeneca, DxS to Commercialize Companion Dx for Iressa in Europe; US Still Uncharted

AstraZeneca is working with DxS to commercialize a EGFR mutation test kit in Europe to identify the patient population most likely to benefit from treatment with non-small cell lung cancer drug Iressa. The company has announced no such plans in the US, where the FDA has restricted any new NSCLC patients from receiving the drug.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.